Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q3 EPS of $4.05, $0.80 better than the analyst estimate of $3.25. Revenue for the quarter came in at $227.9 million versus the consensus estimate of $264 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2021 revenue of $930 million, versus the consensus of $948 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.